Trial · NCT00570713
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | MORAb-009 Plus Gemcitabine ('MORAb-009') | 6.5 | 95% Confidence Interval 4.5 to 8.10 | Months | |
| Overall Survival (OS) | Placebo Plus Gemcitabine ('Placebo') | 6.9 | 95% Confidence Interval 5.4 to 8.8 | Months | |
| Progression-free Survival | MORAb-009 Plus Gemcitabine ('MORAb-009') | 3.4 | 95% Confidence Interval 1.9 to 4.7 | Months | |
| Progression-free Survival | Placebo Plus Gemcitabine ('Placebo') | 3.5 | 95% Confidence Interval 2.8 to 4.9 | Months | |
| Best Overall Response Rate | MORAb-009 Plus Gemcitabine ('MORAb-009') | Complete or Partial Response | 6.4 | percentage of participants | |
| Best Overall Response Rate | Placebo Plus Gemcitabine ('Placebo') | Complete or Partial Response | 7.8 | percentage of participants | |
| Best Overall Response Rate | MORAb-009 Plus Gemcitabine ('MORAb-009') | Complete Response | 0 | percentage of participants | |
| Best Overall Response Rate | Placebo Plus Gemcitabine ('Placebo') | Complete Response | 0 | percentage of participants | |
| Best Overall Response Rate | MORAb-009 Plus Gemcitabine ('MORAb-009') | Partial Response | 6.4 | percentage of participants | |
| Best Overall Response Rate | Placebo Plus Gemcitabine ('Placebo') | Partial Response | 7.8 | percentage of participants | |
| Best Overall Response Rate | MORAb-009 Plus Gemcitabine ('MORAb-009') | Stable Disease | 47.4 | percentage of participants | |
| Best Overall Response Rate | Placebo Plus Gemcitabine ('Placebo') | Stable Disease | 55.8 | percentage of participants | |
| Best Overall Response Rate | MORAb-009 Plus Gemcitabine ('MORAb-009') | Progressive Disease | 19.2 | percentage of participants | |
| Best Overall Response Rate | Placebo Plus Gemcitabine ('Placebo') | Progressive Disease | 23.4 | percentage of participants | |
| Best Overall Response Rate | MORAb-009 Plus Gemcitabine ('MORAb-009') | Not Evaluable | 26.9 | percentage of participants | |
| Best Overall Response Rate | Placebo Plus Gemcitabine ('Placebo') | Not Evaluable | 13.0 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00570713/results